EOS imaging Installs System at Prominent Private Clinic in Switzerland

EOS Imaging (Paris:EOSI) (Euronext, FR0011191766 – EOSI), the pioneer in orthopedic 2D/3D imaging, today announced the installation of the EOS^® system at the Clinique de la Source in Lausanne, Switzerland marking the sixth EOS installation in the country and the first in a private healthcare center in the Vaud canton.

Clinique de la Source, a member of the Swiss Leading Hospitals organization, is globally recognized in orthopedic surgery and treats more than 100,000 patients each year. The Institute of Radiology at La Source is the largest private medical imaging center in the Vaud region of Switzerland where Lausanne is located. As such, this clinic features cutting-edge radiological imaging equipment - now including the gold standard in low-dose stereoradiographic imaging with the EOS^® system.

"Ensuring patient comfort, limiting radiation exposure and ensuring that our imaging offerings are cost-effective for both patients and the Swiss healthcare system are major priorities for the entire La Source team, from radiologists to hospital leadership," said Sylvain Duc, Radiologist at La Source's Institute of Radiology. "The addition of the low-dose EOS imaging system and the enhanced 2D and 3D images it will produce to our already robust imaging offerings will only strengthen the patient care at La Source."

Marie Meynadier, CEO of EOS imaging, said, "The quality of care in orthopedic surgery at La Source led to their decision to adopt EOS^® for their diagnosis, planning and control imaging. We are very pleased by that decision from a leading institution, which contributes to turning EOS into a standard of care on the Swiss market.”

The EOS^® system provides full-body stereoradiographic images of patients in functional positions, in both 2D and 3D. EOS exams require a radiation dose 50% to 85% less than Digital Radiology and 95% less than basic CT scans. The new EOS Micro Dose option, recently cleared by the Food and Drug Administration, allows a further drastic step towards the ALARA principle (As Low As Reasonably Available) by bringing pediatric spine follow up exams at the dose level equivalent to a week of natural background radiation on Earth.

For further information about the Company or EOS®, the first full body, low dose 2D/3D imaging system, please visit http://www.eos-imaging.com/.

EOS imaging has been chosen to be included in the new EnterNext© PEA-PME 150 index, composed of 150 French companies and listed on Euronext and Alternext markets in Paris.

EOS imaging is listed on Compartment C of Euronext Paris

ISIN: FR0011191766 – Ticker: EOSI

Next press release: annual results for 2014 and turnover for the 1st quarter of 2015: on April 20, 2015 (after market).

About EOS imaging:

EOS imaging designs, develops, and markets EOS®, an innovative medical imaging system based on technology that enabled George Charpak to win the Nobel Prize for Physics, as well as associated solutions. The Company is authorized to market in 47 countries, including the United States (FDA), Japan and the European Union (EU). As of December 31, 2014 the Group posted 2014 consolidated revenue of €20.1 million and employed 107 people including an R&D team of 39 engineers. The Group is based in Paris and holds four subsidiaries in Besançon (France), Cambridge (Massachusetts), Montreal (Canada) and Frankfurt (Germany), and offices in Singapore.